Advanced Approaches to Breast Cancer Classification and Diagnosis

M. Zubair¹, S. Wang²* and N. Ali¹*

¹Department of Biology, University of Arkansas at Little Rock, Little Rock, AR, United States, ²Department of Chemistry, University of Arkansas at Little Rock, Little Rock, AR, United States

The International Agency for Research on Cancer (IARC) has recently reported a 66% increase in the global number of cancer deaths since 1960. In the US alone, about one in eight women is expected to develop invasive breast cancer(s) (breast cancer) at some point in their lifetime. Traditionally, a BC diagnosis includes mammography, ultrasound, and some high-end molecular bioimaging. Unfortunately, these techniques detect BC at a later stage. So early and advanced molecular diagnostic tools are still in demand. In the past decade, various histological and immuno-molecular studies have demonstrated that BC is highly heterogeneous in nature. Its growth pattern, cytological features, and expression of key biomarkers in BC cells including hormonal receptor markers can be utilized to develop advanced diagnostic and therapeutic tools. A cancer cell’s progression to malignancy exhibits various vital biomarkers, many of which are still underrepresented in BC diagnosis and treatment. Advances in genetics have also enabled the development of multigene assays to detect genetic heterogeneity in BC. However, thus far, the FDA has approved only four such biomarkers—cancer antigens (CA); CA 15-3, CA 27-29, Human epidermal growth factor receptor 2 (HER2), and circulating tumor cells (CTC) in assessing BC in body fluids. An adequately structured portable-biosensor with its non-invasive and inexpensive point-of-care analysis can quickly detect such biomarkers without significantly compromising its specificity and selectivity. Such advanced techniques are likely to discriminate between BC and a healthy patient by accurately measuring the cell shape, structure, depth, intracellular and extracellular environment, and lipid membrane compositions. Presently, BC treatments include surgery and systemic chemo- and targeted radiation therapy. A biopsied sample is then subjected to various multigene assays to predict the heterogeneity and recurrence score, thus guiding a specific treatment by providing complete information on the BC subtype involved. Thus far, we have seven prognostic multigene signature tests for BC providing a risk profile that can avoid unnecessary treatments in low-risk patients. Many comparative studies on multigene analysis projected the importance of integrating clinicopathological information with genomic-imprint analysis. Current cohort studies such as MINDACT, TAILORx, Trans-aTTOM, and many more, are likely to provide positive impact on long-term patient outcome. This review offers consolidated information on currently available BC diagnosis and treatment options. It further describes advanced biomarkers for the development of state-of-the-art early screening and diagnostic technologies.

Keywords: breast cancer, heterogeneity, novel biomarkers, early diagnosis, multigene assays, biosensors
INTRODUCTION

Cancer cells are misbehaving normal cells that are beyond the paradigm of life and death. Some researchers consider their self-sufficiency and self-management as an evolutionary process in the cell division. Like an organism that evolves through a process of natural selection and mutation, cancer cells also progress through selective transformation to malignancy (Casás-Selves and DeGregori, 2011). The current edition of the International Agency for Research on Cancer (IARC) reports a 66% increase in the global number of cancer deaths since 1960. Currently, breast cancer(s) (BC) is the second most common cancer worldwide, after lung cancer. Accordingly, in the US alone, about one in eight women is expected to develop invasive BC at some point in their lifetime. Considering the number of research articles published on BC diagnosis and treatments, research in its early detection is still lagging significantly (Figure 1). In this review, we aim at providing consolidated information on recent advancements in BC diagnosis and therapy.

BREAST CANCER HETEROGENEITY

BC are heterogeneous in nature, both at the histological and molecular levels. Traditional BC treatments initially depend upon the tumor characteristics such as its clinical stage, histopathologic features, and biomarker profiling. Our understanding of its biological characteristics has improved in the last few decades. We can now subtype it with molecular profiling, hormone indicators, growth factor expressions, and many more. The subtyping of BC is still challenging and very volatile. Different stem cell populations and progenitor cells in the mammary gland can cause a paradigm shift in our current understanding of its heterogeneity.

Histopathologic Heterogeneity

Histological analysis of breast tumors considers its anatomical origin, in most instances, from the junction between the terminal duct and lobule, an area further labeled as “atypical lobules” (Oyama et al., 2000) or hyperplastic enlarged lobular unit (HELU) (Lee et al., 2005). These histologically identifiable lesions are also the earliest precancerous ones reflecting hormone-responsive cancer (Lee et al., 2005). This lesion further exhibits an elevation in estrogen and progesterone receptor (ER-α/PR). Such a histological perspective is essential in chemotherapeutic responsiveness and endocrine therapy study.

According to the 2012 WHO classification, BC are primarily categorized into carcinomas and sarcomas (Sinn and Kreipe, 2013) (Figure 2A). If BC’s inception is from the breast’s epithelial cell-based components, including lobules and terminal ducts (responsible for milk), it falls under carcinomas. It further stretches to the underlying mammary stem cells (MSC) that differentiate into epithelial cells (Liu et al., 2005; Shackleton et al., 2006). Unlike carcinomas that usually ascend from milk ducts, sarcoma originates from the connective tissues, such as blood vessels and myofibroblast, which support the ducts and the lobules. It further represents less than 1% of the total BC.

Significant heterogeneity in breast carcinomas further subcategorizes it into in situ and invasive carcinomas. The in situ carcinomas are more localized to their prevailing lobules and...
ducts. In contrast, the invasive carcinomas penetrate the neighboring tissues and, if not intercepted, could metastasize to other body tissues and organs. The invasive carcinomas, based on their morphology, are further categorized into morphologically identifiable types and no special type (NST) or “not otherwise specified” (NOS) type. Of them all, the invasive ductal carcinoma (IDC) (Siegel and Jemal, 2015) represents the most frequent type of invasive carcinoma (about 80% of all BC) followed by invasive lobular carcinomas (ILC) of special-type, representing 10–15% of BC. Additionally, ILC growth involves penetration of single cells or cells segregated in sheets, with molecular and genetic aberrations different from IDC. Recently, amongst the rare subtypes of invasive carcinomas, two new entities—tall cell carcinoma with reverse polarity (TCCRP) and mucinous cystadenocarcinoma of NST—have been recognized and listed in 2019 WHO BC’s classification (Hoon Tan et al., 2020). Though they both exhibit tall columnar cell morphology, their core contents are different. Mucinous cystadenocarcinoma of NST contains an abundance of luminal mucin with a cytomorphology of pancreatobiliary and ovarian mucinous cystadenocarcinoma. In comparison, TCCRP represents features like papillary thyroid carcinoma and salivary
gland-type tumor. Though they both belong to invasive carcinomas, their malignant potential is low (Hoon Tan et al., 2020).

Additionally, the 3-tier (low, intermediate, and high) grading system further struggles at providing order to the invasive BC-heterogeneity. This grading system analyzes the percentage of tumor in glands and tubular structures (T), degree of nuclear polymorphism or nodes (N), and the mitotic rate (M). However, the stage of a BC is different from its grade. BC staging represents the tumor’s gross appearance, whereas TNM grading allows simplification to BC staging by exhibiting BC’s spread. However, both are heavily incorporated in clinical tools determining the prognosis during BC surgery, such as in Nottingham Prognosis Index (NPI) (Lee and Ellis, 2008).

**Molecular Heterogeneity**

Over time, several molecular biomarkers have been reported subtyping BC based on genomic instability (Kronenwett et al., 2006), cytogenetic pathways (Korschning et al., 2002; Hu et al., 2006), gene expression levels (Perou et al., 2000; Kouros-Mehr et al., 2006), and many more. In modern molecular pathology, high-throughput screening on biomarkers provided a highly desired explanation for BC heterogeneity. It delivers biomarkers—estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) that categorizes BC into five subtypes (Figure 2B): luminal A and B, HER2 enriched, triple-negative or basal-like (BL), and normal-like BC. Stratifying BC will help in expediting the prognosis and treatment selection.

**Estrogen Receptor**

ER is the earliest and one of the most prevalent BC biomarkers used (Ellis et al., 2005; Rakha et al., 2010). Many cohorts and cooperative studies with a combined-data set suggest that about 80% of all BC are ER-positive (ER+). It is mainly well-differentiated, less aggressive, and great at prognosis than ER-negative (ER−) BC (Figure 2B). Based on the stem-cell cancer model, the ER− BC ascends from the most primitive stem cells, where specific mutations limit its differentiation into ER-positive (ER+) cells (Prat and Perou, 2009). A broader gene expression profiling (GEP) on approximately 500 genes “intrinsic factors” further differentiate ER− BC into luminal-A and -B subtypes with different overall survival (Sorlie et al., 2003). Sorlie and his colleagues observed a high expression of luminal genes and ER− related genes (such as PR) in the luminal-A subtype (Sorlie et al., 2003) than luminal B subtype (Figure 2B). Likewise, the luminal A subtype exhibits a greater prognosis and overall survival than the luminal-B subtype. Consistently, a poor response to endocrine therapies of the luminal-B subtype corroborates with the low ER/PR-expression (Bardou et al., 2003; Creighton et al., 2009; Creighton et al., 2010), high Ki-67 expression (Musgrove and Sutherland, 2009), and an unusual overexpression of HER2 (Ellis et al., 2006) (Figure 2B). As such, Ki-67, the proliferative biomarker, is also suggested as an additional clinical biomarker in differentiating luminal-A from luminal-B subtypes.

**Progesterone Receptor**

PR is an ER-regulated gene critical for the lobuloalveolar development of mammary glands (Brissen, 2002). Unlike estrogen and its receptor (ER) that induce ductal outgrowth of mammary glands, progesterone and its receptor (PR) regulate ductal morphogenesis (Atwood et al., 2000). A localized PR cluster stimulates the mammary glands’ side-branching by inducing insulin-like growth factor1 (IGF-1) (Ruan et al., 2005). It serves as a negative indicator of tumor aggression in that PR− BC is more aggressive than PR+ BC (Cui et al., 2005) (Figure 2B). Thus, both ER and PR are functionally intertwined in mammogenesis, and assessing them together as double receptors will guide the hormonal therapy response.

Taken together, both the receptors have four subcategories under luminal A and B subtypes: ER+/PR+, ER+/PR−, ER−/PR+, and ER−/PR−. A double-positive subtype—ER+/PR+—has a better prognosis, and it is more responsive to endocrine therapy (Figure 2B). In a study on subclasses that lack PR expression in the ER+ subset, Rakha and colleagues observed a less receptiveness toward endocrine treatment such as tamoxifen (Rakha et al., 2007) compared to the double-positive subtype (ER+/PR+) (Dowsett et al., 2006). Double-negative—ER−/PR−—exhibits a higher relapse rate with the worst prognosis and overall survival rate. ER−/PR− BC acts as an apt candidate for chemotherapy after an unresponsive treatment to endocrine therapy (Bardou et al., 2003). ER−/PR− BC can further be stratified based on a third biomarker, HER2 (Sorlie et al., 2003), thus introducing triple receptor classification.

**HER2 Receptor**

The BC’s insensitivity to endocrine therapy in a triple receptor classification is rooted in an unusual overexpression of HER2 receptors on mammary glands. It is a transmembrane protein-tyrosine kinase receptor present on normal mammary gland epithelial cells. However, overexpression of about 20%, which establishes genetic instability and excessive proliferation, is regarded as HER2 positive (HER2+) BC subtype (Slamon et al., 1989). Also, intimate crosstalk between HER2 and ER/PR signaling pathways corroborates its resistance to endocrine therapies (Schiff et al., 2004; Rakha et al., 2007). This crosstalk excludes ER/PR expression deletion through selective ER modulators (SERM) (Ellis et al., 2001) inhibitors. Similar to luminal A and B subtype, as defined by GEP (Perou et al., 2000), the three receptor-based immune histochemical/compatibility (IHC) evaluation stratifies BC into ER+/PR− HER2+, ER+/PR− HER2−, and ER+/PR+ HER2+, where all HER2+ cases shared similar genetic variations (Perou et al., 2006; Cheang et al., 2009) and outcomes (Network, 2012), irrespective of their hormonal subsets (Figure 2B). Preclinical and clinical studies of patients with HER2 BC reports promising results upon merging chemotherapy with anti-HER2 monoclonal antibodies (trastuzumab and pertuzumab) (Piccart-Gebhart et al., 2005) and tyrosine kinase inhibitor (lapatinib and neratinib) based therapies (Cuzick et al., 2011). Furthermore, HER2+ BC subtypes, regardless of its ER status, benefit from paclitaxel (a plant alkaloid based chemotherapeutic agent) after adjuvant
treatment with an anthracycline-based regimen such as doxorubicin plus cyclophosphamide, specifically in node-positive breast tumors (Hayes et al., 2007; Blum et al., 2017). In conclusion, ER+/PR+/HER2+ BC has the best prognosis and shows an effective treatment response to chemo-hormonal therapy (Cuzick et al., 2011; Lehmann et al., 2011).

Triple-Negative Breast Cancer

TNBC subtype includes the most aggressive and highly heterogeneous of all BC subtypes. The lack of ER, PR, and HER2 leads to a higher staged nuclear grade cancer with intense mitotic activity and equally poor prognosis (Figure 2B). Due to no hormonal expression, TNBCs are tolerant of endocrine and targeted therapies. Within the last decade, TNBC stratification has been updated frequently. Initially, Lehmann and colleagues, based on GEPs and ontologies from 587 TNBC cases, classified TNBC into six subtypes: BL1, BL2, mesenchymal (M), mesenchymal stem-like (MSL), immunomodulatory (IM), and luminal androgen receptor (LAR) (Lehmann et al., 2011). Whereas, recent findings, based on GEP analysis of most upregulated mRNAs and long non-coding RNAs (lncRNAs) (Liu et al., 2016), merged two subsets IM and MSL into "mesenchymal-like" and Basal1/2 into "BL" to give a most recent classification of four TNBC subtypes (Liu et al., 2016). Though the incursion of LAR assessment into the TNBC subtype requires further investigation, the components involved in the PIK3 pathway is worth considering while developing a targeted therapy (Chia et al., 2015). The IM-TNBC subtype accounts for all the immune-cell associated biomarkers and gene products such as antigen-presenting cells (APCs), chemokines, cytokines signaling components, etc. (Liu et al., 2016). Therefore, in this subtype, targeting immune checkpoints could provide beneficial therapeutic outcome.

Mesenchymal-like TNBC subtype (MES) expresses genes with epithelial-mesenchymal transition (EMT) signature and stem-cell-like properties. It primarily includes cell migration-related signaling pathways such as extracellular matrix-receptor interactions pathways, Wnt pathways, TGFβ signaling, breast stem cells biomarker, ALDH1A1, and other stem cells-oriented genes. It is also called metastatic BC (Lehmann et al., 2011) and is associated with cell differentiation pathways (Lehmann et al., 2011), which could be due to its high motility-related gene expression. Since MES is associated with growth factors, EMT-targeted chemotherapeutic drugs may benefit the patient (Gibson et al., 2005).

BL subtypes are associated at the mammary gland’s basal/myoepithelial level, exhibiting overexpression of cell-proliferative biomarkers such as cell-cycle checkpoints, DNA repair, and replication related genes (Lehmann et al., 2011). Burstein’s reclassification of TNBC subtypes highlights BL subtype exhibiting either downregulation of immune regulating genes—BL-immune-suppressive (BLIS)—and an upregulated immune response—BL-immune activated (BLIA)—TNBC subtype (Burstein et al., 2015). The prognosis index recorded the order in disease-free survival of BL-TNBC subtype—BLIA > M > LAR > BLIS (Burstein et al., 2015). This order could be due to the tumor-infiltrating lymphocytes (TILs) found in the microenvironment of BLIA. The presence of TILs in the BLIA subtype of TNBC could further guide adjuvant chemotherapy treatments. In 2014, the International TILs group proposed facilitating TILs as a stratification factor or one of the significant parameters to assess heterogeneity in BC by hematoxylin and eosiん staining evaluation (Salgado et al., 2015).

Traditional BC classifications that include IHC-hormone evaluations, GEP analysis, and examining pathological features have become clinically affordable in routine lab checkups. However, not all transcription synchronizes with the corresponding protein expression. Numerous factors, such as mRNA transcription rate, protein stability, post-translational modifications, and random mutations, affect proteins used as molecular biomarkers. Therefore, for complete knowledge on pathological changes in BC, high-throughput analysis of data extracted from several ‘omics’ studies such as genomic, proteomic, transcriptomic, epigenetics, and Next-Gene Sequencing (NGS)—is needed for analyzing potential biomarkers and pathways involved. However, it still is a long bridge between research findings and its clinical implementations.

Androgen Receptor

Another potential hormonal receptor—androgen receptor (AR)—is a prevalent sex steroid hormone used in BC subtyping (Labrie et al., 2003). In ER− BC, androgen and its receptor promote cell proliferation and spread (Safarpour et al., 2014) by acting at different components of AR-signaling pathways (Rahim and O’Regan, 2017). The AR is highly expressed in the LAR subtype, with mRNA level nine times or more than any other TNBC subtype (Lehmann et al., 2011), reflecting one-third of TNBCs (Mrklič et al., 2013). IHC analysis also detected a high expression of downstream components of AR-signaling (Mrklič et al., 2013). Therefore, anti-AR therapy is recommended for TNBC patients. In April 2020, the phase II trial showed promising results in its anti-androgen hormone—“bicalutamide”—study in treating metastatic BC patients (updated on ClinicalTrials.gov, Identifier NCT00468715). If the results came through as expected, AR assessment could be integrated into the standard test of TNBC subtypes.

BC BIOMARKERS: ESTABLISHED AND PROMISING

BC’s systemic management initially considers the expression level of the cell-proliferation gene (Ki67) and hormonal receptors (HR, PR, and HER2) before assessing its subtype clinicopathological and biological parameters. However, various scientific studies also reported some underrepresented single biomarkers (Figure 3). At present, only four such biomarkers—cancer antigens (CA); CA 15-3, CA 27-29, HER2, and circulating tumor cell (CTC) are approved by FDA in assessing BC in body fluids.
The American society of clinical oncology (ASCO) recommends the gene expression analysis of CA 15-3 (mucin1 (MUC1) gene) and CA 27-29 together with bio-imaging for constant monitoring of treatment’s persistence (Van Poznak et al., 2015).

CTCs are approved by the FDA in 2004 to be used in the CellSearch system for measuring and monitoring the metastasis of breast, prostate, and colorectal cancer (Cristofanilli et al., 2007). This CellSearch system analyzes the expression of EpCAM, CD-45, cytokeratin (CK)-8,-18, and CK-19 in body fluids (serum or blood) (Figure 3). In a large cohort of breast carcinoma (575 cases), Shao and colleagues observed that about 90% of all BC exhibit an expression of CK-7, -8, -18, and -19 (Shao et al., 2012). Furthermore, an expression of CK-7 in conjunction with CK-8 showed the utmost sensitivity at detecting BC, especially within high-grade tumors (Shao et al., 2012). Though it promises instant liquid biopsy, the scientific community raises some concerns about the heterogeneity and the low frequency of CTCs, making the detection a bit challenging. However, the addition of more molecular markers such as BSL-2 (Smerage et al., 2013), HER2, EGFR (Zhang L. et al., 2013), CD44, CD47, MET (Baccelli et al., 2013), and many more could assist in rectifying this issue. Nonetheless, this “CellSearch” system is still in its infancy. With a half-life ranging from one to 2 h in BC, CTC fails at guiding subtype-specific therapies (Alix-Panabières and Pantel, 2014).

**BRCA1 and BRCA2**

Breast CAncear genes-1/-2 (BRCA1/2) are the most common genes implicated in BC risk. Their translated products are phosphoproteins localized in the nucleus (Chen et al., 1996; Bertwistle et al., 1997). BRCA1 protein regulates cellular pathways such as gene-transcription regulation, cell proliferation, DNA repair response, etc., whereas BRCA2 protein regulates DNA repair pathway (Sharan et al., 1997). Early studies on germline mutation in the BRCA1 gene found that the normal allele or the wild type (WT) copy was deleted in the event of BRCA-related cancers (BC or ovarian cancer). The loss of wild type BRCA1 (or loss of heterozygosity) gene in tumor samples reveals its role as a tumor suppressor gene (Smith et al., 1992). Moreover, Arizti and colleagues observed regulatory parallels between BRCA1 and tumor suppressor p53 (Arizti et al., 2000) (Figure 3). Authors further suggested an interesting pathway connecting p53 and BRCA1 genes and that their loss under stress conditions could be integral to tumorigenesis (Arizti et al., 2000). In a separate study, loss of function mutation (frameshift or deletion/duplication) in BRCA1 shown to result in genomic instability with increased susceptibility to malignancy (Deng, 2006). More than sixteen hundred mutations, predominantly frameshift mutations, have been reported so far in the BRCA1 gene (Godet and Gilkes, 2017). In circumstances where a mutated copy of the BRCA1/2 gene gets inherited from either parent, the offspring becomes more susceptible to develop BC. However, a single mutated gene doesn’t always result in BC. Only the second mutation or the second defective gene that could affect the wild-type gene triggers BC development. Furthermore, since all cells carry similar genetic imprint, a non-inherited BRCA gene mutation is strictly tissue-restricted to the tumor region (breast or ovarian region) (Prevention, 2020; Singh and Yu, 2020). The BRCA1/2 carriers display a histological characteristic of poorly differentiated high-grade tumors (Musolino et al., 2007). Its metastasis into neighboring vessels indicates a higher risk of contralateral BC (Verhoog et al., 1998; Brekelmans et al., 2007). Mavaddat and his colleagues anticipated the risk to be approximately 83% in BRCA1 and 62% for BRCA2 heterozygotes by age 70 (Mavaddat et al., 2020).
TP53 isoforms

...utterly. In a cohort of 127 BC cases, of three interdependent cross-reactivity against any other p53 isoform. These mutant-common polymorphic region of TP53 (Hwang et al., 2018), monoclonal antibodies developed recently recognizes the most... with different cancers. On the other hand, not all of them... can yield truncated isoforms which are associated with the DNA repair mechanism. Its mutation in women exhibits a greater risk of BC (Thompson et al., 2005). Since it associates with an autosomal recessive disease, patients homozygous for it will be primarily affected. In contrast, the heterozygous patients live an everyday life, but their chances of developing BC are approximately two to four times higher than the general population. An extensive metadata analysis of nineteen heterogeneous cohort studies on relatives of patients suffering from AT syndrome suggested that the comparative risk of BC is 6.02% by 50 years of age (95% credible interval: 4.58–7.42%) and 32.83% by 80 years of age (95% credible interval: 24.55–40.43%) (Marabelli et al., 2016) than the general population. Begam and her colleagues also recently concluded their study on aberrant ATM promoter methylation as a biomarker to detect BC in patients (Begam et al., 2017) (Figure 3). However, the hurdle in its biomarker role is its relative infrequency of mutation and high prevalence of variants.

Phosphatase and Tensin Homolog

PTEN gene mutation is implicated in a wide variety of sporadic cancers (Milella et al., 2015). It is majorly associated with cellular functions such as genomic stability, cell proliferation, and motility through PI3K dependent/independent pathways. In an invasive BC study on 3,824 patients, an average of 7% exhibited germline mutation in their PTEN gene (Gao et al., 2013) (Figure 3). Moreover, although PTEN’s mutations aren’t prominent, its loss frequency is approximately 30–40% in BC, accounting for about 25% in HER2+ BC (Zhang H. Y. et al., 2013; Veeraraghavan et al., 2017). Furthermore, its insignificant protein expression levels led to investigating/detecting its mRNA levels much more efficiently than its IHC analysis. Likewise, numerous studies have also highlighted the cases where PTEN’s loss status fails to correlate with drug treatment response in BC patients. In the tamoxifen plus everolimus (TAMRAD) and the BC Trials of Oral Everolimus-2 (BOLERO-2) studies, PTEN’s status fails to correlate with the response to everolimus treatment in BC patients (Treilleux et al., 2015). Moreover, studies on HER2+ BC further reported an unsuccessful association between PTEN loss and anti-HER therapy response (trastuzumab and lapatinib) (Fujita et al., 2006; Nuñorfo et al., 2015). Therefore, clinicians should also combine other pathological parameters of BC besides analyzing PTEN gene expression.

Seven in Absentia Homolog

A growth factor activated RAS pathway is responsible for uncontrolled cell growth, proliferation, and dissemination in various human cancers (Schmidt et al., 2007). In BC, the RAS pathway is an understudied pathway due to an insignificant detection of RAS mutations in mammary tumors (only in about 5% of the BC patients) (Arteaga et al., 2012). Further, it has been observed that the most downstream and an essential component of the EGFR/HER2/RAS pathway is an evolutionarily...
conserved E3 ligase—SIAH—that acts as a “gatekeeper” to tumorigenesis (Medhioub et al., 2000; Schmidt et al., 2007). Behling and colleagues found that its expression was proportional to the progression of ductal carcinoma in situ (DCIS) to invasive carcinoma (Behling et al., 2011). Though it is the most downstream component of the pathway, inhibiting SIAH expression or its enzymatic activity inhibits the RAS-mediated tumor growth and metastasis in nude mice (Schmidt et al., 2007). The inhibitory effect of reduced SIAH expression may affect the upstream of the pathway, as a feedback loop mechanism. Its enzymatic activity may be nurturing/fostering the tumor cells by modulating its microenvironment. Clinically, it can be recognized in combination with EGFR or alone as a surrogate biomarker guiding chemotherapy treatment by analyzing the depth and recurrence of chemoresistant tumor clones (van Reesema et al., 2016). Its on and off expression reflects the aggression and repression in post-neoadjuvant chemotherapy patients, a prognostics that outperform the HR/HER/Ki67 as a new biomarker (van Reesema et al., 2016) (Figure 3). Furthermore, based on its expression and enzymatic alterations, expectations are to develop a targeted therapy against SIAH, alone or in combination with EGFR, for chemoresistant, relapsed, late-stage, and metastatic BC.

SIAH is an evolutionarily conserved gene, and its mutations rarely account for any specific disease (Medhioub et al., 2000; Schmidt et al., 2007; Zhao et al., 2016). Some research groups have observed SIAH1 gene mutations in certain carcinomas such as hepatocellular carcinoma, prostate cancers, breast cancers, etc., whereas the results were hard to interpret because of the interference of other tumor suppressor genes located on the same chromosome (Medhioub et al., 2000; Zhao et al., 2016).

Insulinoma-Associated Protein 1

In 2003, the WHO incorporated a classification of BC with neuroendocrine (NE) differentiation features (Lakhani et al., 2012), which was first reported in 1963 for its correlation with BC. The classification was further revised to carcinomas of neuroendocrine features in the 2012 WHO classification of BC (Bussolati and Badve, 2012; Lakhani et al., 2012). Its subgroup, invasive breast carcinoma (IBC) with neuroendocrine differentiation (IBC-NE), is a rare subtype predominant in postmenopausal women. In a large IBC cohort, Razvi and his colleagues evaluated a biomarker—INSM1—for NE differentiation using IHC (Razvi et al., 2020). According to the authors, in about 7% of the cases, the INSM1-IHC expression profile was found comparable or more sensitive than predefined NE biomarkers: chromogranin A and CD56, but less sensitive than synaptophysin (Razvi et al., 2020). INSM1 was initially reported, by Goto and colleagues, to be in the fetal pancreas and nervous system as a zinc finger transcription factor (Goto et al., 1992). Most recently, it has been observed in high grade and aggressive breast carcinomas, particularly among luminal-B subtypes (Wachter et al., 2014; Razvi et al., 2020). The authors further suggested INSM1 expression as a favorable prognostic biomarker (Figure 3), which could be useful in stratifying NE-tumors (NET) with different prognosis (Razvi et al., 2020).

Matrix Metalloproteinase-9

Matrix metalloproteinases (MMP) are a family of endopeptidases acting on a broad range of proteins such as gelatin, collagen, and elastin (Kessenbrock et al., 2010). MMP-9, also known as gelatinase B, is an extracellular protease that remodels the tumor environment by degrading the endothelial basement membrane (Kessenbrock et al., 2010). The disrupted membrane enables carcinoma invasion and triggers angiogenic switch, a necessary step in tumor progression (Gialeli et al., 2011; Mehner et al., 2014). MMP-9 also activates soluble factors such as cytokines, which induce EMT and invade microenvironment of distant organs, promoting metastasis (Gialeli et al., 2011; Mehner et al., 2014). Its expression is regulated by various pathways, such as MAPK, ERK, EGFR/P13K (Dziembowska and Wlodarczyk, 2012; Shi et al., 2015), implicated widely in BC. MMP-9 is considered as a potential biomarker in various cancers (Tian et al., 2008; Li et al., 2012; Li L.-N. et al., 2013; Blanco-Prieto et al., 2017; Chen et al., 2018; Zhou et al., 2018) (Figure 3). In BC, MMP-9 expression varies with its molecular (intrinsc) subtypes (Yousef et al., 2014). Yousef and colleagues observed a signature expression of MMP-9 in HER2+ and TNBC subtype with node-positive breast carcinoma (Yousef et al., 2014). Multivariate serum analysis for MMP-9, together with the extracellular domain (ECD) of HER2 (HER2-ECD) and neuron-specific enolase (NSE) (a non-specific NE biomarker), was able to discriminate between BC patients for brain metastasis (Darlix et al., 2016). Furthermore, a non-invasive multivariate exploration could stratify BC patients based on serum MMP-9 expression in conjunction with Rho expression in circulating leukocytes (Golubnitschaja et al., 2017) for BC risk assessment.

MMP-9 polymorphisms have been associated with many diseases such as pancreatic ductal adenocarcinoma (Tian et al., 2008), ovarian and cervical cancer (Li et al., 2012; Li L.-N. et al., 2013), lung cancer (Blanco-Prieto et al., 2017), bone tumor (Varn et al., 2017; Chen et al., 2018), atherosclerosis. However, its relationship with BC’s occurrence is still unclear (Felizi et al., 2018).

Salivary Biomarkers

Investigating the saliva’s protein profile for discriminatory cancer biomarkers has been shelved for decades due to technological limitations. Recently, salivary metabolite profiling has received much attention as a noninvasive biomarker for early BC detection. Zhang and colleagues (Streckfus et al., 2006) initiated a de novo biomarker discovery approach in saliva (Zhang et al., 2010). The study established a total of nine biomarkers, eight mRNAs (S100A8, GRIK1, GRM1, H6PD, IGFB2BP1, CSTA, MDM4, and TPT1) and one CA protein-6 (CA-6), with a clinical diagnostic accuracy of 92% (Zhang et al., 2010) (Figure 3). The protein, CA-6, was also found to be a marker in an earlier study on saliva samples of DCIS patients (Streckfus et al., 2006). Subsequent studies found an altered metabolism for approximately 28 different metabolites (Sugimoto et al., 2010), such as valine, proline (Cheng et al., 2015), taurine, lysine, and sialic acid (Ozturk et al., 2011), statistically discriminating BC from healthy controls. Moreover, Laidi and colleagues suggested that salivary
autoantibodies could play a role in BC screening (Laidi et al., 2016). In conclusion, saliva-based biomolecules have shown growing importance in salivary biomarker discovery for future research. However, ASCO has not yet endorsed the use of salivary biomarkers as diagnostic tools for BC.

**Tumor-Associated Autoantibodies**

TAABs are antibodies produced by a patient’s immune cells against tumor-associated antigens (TAAs) that are comparatively overexpressed in cancer cells (Laidi et al., 2016). The body’s immune system recognizes TAAs as foreign entities and triggers an acquired immune response to produce TAABs. These antibodies are an amplified “tumor signal” that may fulfill the biomarker features of cancer, i.e., specificity and sensitivity (Figure 3). With the advancement in technologies, such as serological proteome assay (SERPA), serological analysis of protein modifications (MAPPing), and many more, novel immune biomarkers of BC have been discovered and utilized in the early detection of antigens such as TP53, HSP60, Mn-SOD, cyc-B1, c-myc, and so forth (Hamrita et al., 2008). However, these TAAs are aberrantly expressed or post-translationally modified or irregularly regulated in tumors. It is, therefore, evident that a single TAA-targeted TAAB isn’t sufficient for BC detection. A set of multiple TAA-targeted TAABs followed by validation through traditional techniques such as enzyme-linked immunosorbent assay (ELISA), antigen array, and many more could discriminate cancer cells against healthy control. Kim and colleagues successfully devised an autoantibody-based bead array panel of 35 TAAs in a multiplexing assay with an accuracy of approximately 91% (Kim et al., 2009). Noninvasive and simplified detection of TAABs paved the way for its future research as diagnostic biomarkers. Although these TAABs show a strong titer, their heterogeneous nature—due to TAAs’ post-translational modification (PTM)—and our inadequate understanding of humoral response, limit their clinical applications.

**BREAST CANCER DIAGNOSTICS**

**Mammography**

Traditionally, mammography has been used as a gold standard in the screening of BC (Society, 2019). It is a low dosed X-ray exam for each breast, examining breast lumps, skin changes, and nipple discharge or thickening. The digital images, known as a mammogram, are taken both horizontally and vertically to cover a breast to its entirety. These mammograms interpret for mass/lesions, calcifications, and architectural distortions in the breast tissue (Barazi and Gunduru, 2019). Mammography detects such mass/lesions relatively at a stage when the mass has already progressed into a tumor. The interpretations are reported in a Breast Imaging Reporting and Data System (BI-RADS) to communicate with the physician for further assessments (Reporting, 2003). Despite being the gold standard in breast screening, it has significant limitations. The rate of false-positive is significantly high (Hubbard et al., 2011). An increase in fibro-glandular breast tissue density increases the chance of masking or mimicking the underlying BC in a mammogram because both dense tissue and cancer appear white (Boyd et al., 2007). Also, women may fail to inform about their breast implants, leading to misidentification (Society, 2019). Moreover, though a low dose, radiation generated health concerns among patients (Hauge et al., 2014). Out of these limitations, clinical trials are in session evaluating if mammography can be substituted by other advanced techniques such as MRI (Moy et al., 2009) or digital breast tomosynthesis (DBT) (Society, 2019). DCIS or lobular carcinoma in situ (LCIS) and IDC, mammography is the best, superior to MRI and ultrasound. Yet, for detecting ILC, a biopsy is more suitable than mammography (Society, 2019).

**Molecular Imaging**

Magnetic Resonance Imaging (MRI) is a standard technique that uses a magnetic field, in contrast to X-rays in mammography, to analyze the lumps in the breast that later need to be biopsied (Society, 2019). Several modifications have been incorporated in MRI over decades. For example, a contrast reagent, such as gadolinium diethylenetriamine penta-acetic acid (GD-DTPA), is injected into the bloodstream, followed by MRI detection to enhance the images in pinpointing the suspected area for further analysis. Similarly, radioactive chemicals (in Breast Specific Gamma Imaging (BSGI) or Scintimammography) or radioactive particle conjugated with a sugar moiety (in Positron Emission Mammography (PEM)) can be injected intravenously to study the spread of BC and to follow up on patients. With technological advancement in MRI based techniques such as dynamic contrast-enhanced MRI (DCE-MRI) (Chang et al., 2016; Rahbar and Partridge, 2016), chemical exchange saturation transfer MRI (CEST-MRI) (Cai et al., 2014), etc., evaluating metabolic heterogeneity within tumors becomes feasible. However, the requirement of sophisticated equipment constraints its availability to all hospitals/clinics. The exposure to radioactive materials and expenses involved further limit a patient’s willingness to a yearly checkup. As a result, they are recommended only to high-risk women patients (Society, 2019).

**Ultrasound**

As a complementary procedure, ultrasound is a follow-up examination to confirm a positive mammogram (Society, 2019). Several reports have supported the use of automated breast (AB) ultrasonography (ABUS) over mammography for dense breast tissue exams (Kolb et al., 2002; Society, 2019). Contrast-enhanced ultrasonography (CEUS) and microvascular imaging successfully discriminate malignant and benign tumors by analyzing blood flow dynamics in local tissues (Li Y.-J. et al., 2013). CEUS further guides or predicts the effects of neoadjuvant chemotherapy on BC patients (Amioka et al., 2016). As a supplement to mammography, ABUS identifies an additional 1.9 cancer cases per 1,000 women screened (Brem et al., 2015). However, it requires a quality interpretation by an experienced radiologist to minimize false positives.
Digital Imaging/Spectroscopy

Recently, three new noninvasive technology have emerged promoting BC screening and diagnosis—digital infra-red thermal imaging (DIIT), digital image-based elastography (DIET), and electrical impedance scanning/spectroscopy (EIS).

DIIT measures a localized skin temperature difference to reflect the physiological changes such as vasodilation, neovascularization, inflammation, lymph dysfunction/congestion (Anbar, 1998), and other suspicious activities around the breast borders (sternum or axilla). The changes recorded by the infra-red camera are graphed into a heat map around the breast borders. The changes in the breast, also called a thermogram. However, due to its low accuracy, its clinical application is limited. With the recent development of a high-resolution infrared camera, a new interest has been generated in its usage as a BC detection tool.

DIET utilizes the vibrational energy in graphing the location of the tumor (Lee et al., 2014). Sinusoidal waves of low-frequency vibrations (5-100 Hz), as a result of surface motion, are induced in the breast, and the oscillations are recorded by digital cameras tracking fiducial markers (Brown et al., 2007; Peters et al., 2009). Areas with a different surface vibrational response compared to control tissues are considered potentially the tumor infected areas. Feeding these responses to an algorithm allows an evaluation of the phase delay in surface-vibrations, thereby detecting the tumor's angular location, depth, and size (Peters et al., 2008). Clinically, it can detect small tumors that may have gone undetected by an experienced clinician, who depends on manual palpation as the initial diagnosis. Moreover, it can reduce false positives as a screening method, thereby preventing unnecessary radiation and discomfort. However, it cannot provide information on the subtype of BC involved (Ganau et al., 2015).

EIS measures the electro resistance (bio-impedance) (Jossinet, 1996) with the principle that tissues have different electrical properties under different metabolic conditions (Morimoto et al., 1990). The multi-frequency EIS measures the tissue's overall bio-impedance/resistance by varying frequencies (50 samples), ranging from 300 Hz to 10 MHz (Jossinet, 1996). Since a disease (like cancer) creates finite metabolic changes in tissues, EIS can discriminate diseased tissues from normal tissues by analyzing the amount of impedance contributed by different cellular components, including the extracellular environment (Alzurq et al., 2016). For example, at low frequency (<1000 Hz), an electric current will pass through the extracellular fluid only, but at higher frequencies (10 kHz–10 MHz), it can conduct through both intracellular and extracellular spaces (Morimoto et al., 1990; Jossinet, 1996; Chauveau et al., 1999). Clinically, the EIS spectrum of higher frequencies is found more relevant at detecting malignancies (Ollmar and Grant, 2016). Using EIS, Haeri and colleagues successfully separated BC patients from healthy patients by accurately measuring the cell shape, structure, depth, intracellular and extracellular environment, and lipid membrane compositions (Haeri et al., 2016).

Biosensors

Biosensors' inception can be traced back to Leyland's lab in 1956, where the Clark electrodes were invented to detect blood-oxygen (Clark, 1956). Since then, remarkable modifications have been documented in biosensors to sense any abnormality that could result in disease. Biosensors consist of three key components: a receptor, a biomarker, and a transducer (Figure 4). Besides cell surface biomarkers, their shed off ECDs also act as potential biomarkers (Marques et al., 2014). Multiple bioreceptor—biochemical recognition elements (BRE)—are employed to detect such biomolecules in a sample. Biotransducer converts positive interactions between biomarker and bioreceptors into measurable signals (Marques et al., 2014). An adequately structured biosensor is portable in nature with user-friendly features. Its non-invasive and inexpensive point-of-care analysis provides a quick response without compromising its specificity and selectivity (Nikhil et al., 2016).

In a biosensor, BRE is the most versatile component. It could be any entity with specificity toward a biomarker such as antibodies, aptamers, enzymes, CTCs, and many more (Figure 4). In this regard, antibodies are the most common BREs used in biosensors. Contributing to real nano-sense at detecting BC, antibodies have created a commercial niche in BC diagnosis. With recombinant antibodies—a third-generation antibodies—that contains modified antigen-binding domains, the sensitivity limitations that were previously associated with traditional—poly- or monoclonal—antibodies, can now be overcome (Haurum, 2006). It could detect BC biomarkers directly (Sonuç and Sezgintürk, 2014; Eletxigerra et al., 2015) or indirectly by using enzymatic probes (for example, HRP) (Yang et al., 2011), fluorescence probes (Chang et al., 2011) or cross-linkers (Wang et al., 2014; Arkan et al., 2015). However, the thermal instability of antibodies and the tests' reproducibility are still a challenge and need further research.

Researchers have designed a string of specific nucleotide/peptide sequences, which function on the same principle as antibodies but one-third of the size, as tight target binders known as aptamers. Peptide aptamers and nucleic acid aptamers (NAAs) can bind specifically with high affinity to biomolecules, circulating in body fluids, such as glycoproteins, microRNA (Won et al., 2013), and most recently to whole cells (Rong et al., 2016). Interestingly, nucleotide aptamers are selected from a large DNA/RNA library through a combinatorial process—systemic evolution of ligands by exponential enrichment (SELEX)—used in molecular biology for producing ligand-specific oligonucleotides (Tuerc and Gold, 1990). Aptamers bind because they “fit” their targets. With remarkable folding properties, aptamers make secondary and tertiary structures of ssDNA or RNA interacting with the BC biomarkers (Chambers et al., 2008). Its binding to the target is determined by how the bases are stacked, the intercalations, and the target's hydrophobic interactions. These physical parameters can be chemically refined to bind a variety of targets with specificity. Unlike antibodies, aptamers are easily chemically modifiable by conjugation chemistry to provide greater thermal stability and reduced toxicity. Several researchers have
designed aptamer for HER2 (Chun et al., 2013; Qureshi et al., 2015), EpCAM (Song et al., 2013), MUC1 (He et al., 2012; Hu et al., 2014), VEGF (Zhao et al., 2011) and nucleolin (Feng et al., 2011) for early BC detection.

Besides aptamers and antibodies, cDNA based hybridization biosensor has been investigated in various BC detection studies (Figure 4). In one study, the detection of microRNAs (Zhang et al., 2016) and the BRCA1 gene (Cui et al., 2017) have been permitted using a modified cDNA hybridization technique. The hybridized complex formed between cDNA and the target was further amplified in real-time by a DNA polymerase enzyme, right at the electrode. The authors additionally observed an exponential increase in the signal, which shortens the analysis time while keeping the sensitivity and selectivity intact (Benvidi et al., 2015).

Similarly, compatibility between BRE and biotransducer is of utmost importance for a useful biosensor. Several modifications have been made in biotransducers to quantify the acquired signal in proportion to the analyte concentration (Nikhil et al., 2016). Modifications such as, optical transducers (Dey and Goswami, 2011), electrochemical (Grieshaber et al., 2008), piezoelectric biotransducers (Pohanka, 2018), thermometric and magnetic-based transducers etc. have been employed by various researchers for targeting BRCA1 (Culha et al., 2004; Benvidi et al., 2015), HER-2 (Chang et al., 2011; Marques et al., 2014), MUC1 (Chang et al., 2011; Hu et al., 2014), miR-21 (Torrente-Rodriguez et al., 2015; Li D. et al., 2016), EpCAM (Arya et al., 2013), etc., in early BC detection. Also, nanoparticle enhancers were employed alongside with biotransducers to generate an amplified readout signal. Surface plasmon resonance (SPR) biotransducers that provide real-time sensing by analyzing the changes in refractive index upon interaction with labeled biomolecules has recently been used in conjunction with nanoparticles, resulting in the enhancement of the sensitivity of detecting biomarkers such as CA15-3 (Liang et al., 2012), HR (Neo et al., 2009), and MUC1 (Li Y. et al., 2016). In the past few years, research in quantum dots (QDs)/nanocrystals has gained momentum in early BC detection. QDs as nano-labels, structurally, provide a better platform for antibody/protein/aptamer conjugation that can target biomolecules such as tumor-associated exosomes (Boriachek et al., 2017), CTCs (Wu et al., 2018), etc. In a study, Cheng and colleagues designed a three-component DNA construct containing—MUC1 multi-peptide aptamer stem, QDs-reporter, and a quencher—that detects MUC1 peptide at a nano-molar level (Cheng et al., 2009). Freitas and colleagues successfully screened HER2ECD biomarkers in human serum by combining QDs to electrochemical immunosensing (Freitas et al., 2020). The entire screening was completed within 2 h, with hands-on-time of less than 30 min (Freitas et al., 2020). Compared to enzyme-based label systems, the QD label electrochemical sensing eliminates the
**TABLE 1** List of genes/proteins common in the different multigene test analysis. All abbreviations are widely known and are procured following the HGNC and IPNC guidelines. Color coding reflects common genes/proteins included in multiple testing panels.

| Gene | Oncotype-Dx | Prosigna | Mammaprint | IHC4 | EndoPredict | BCI | Mammostrat |
|------|-------------|----------|------------|------|-------------|-----|------------|
| **BCL2** | BCL2 | CENPA | CENPA | BIRC5 | BIRC5 | ALDH1A1 | BIRC5 | CENPA | TP53 |
| **BIRC3** | BIRC3 | | | | | BUB1B | | | HTF9C |
| **CCNB1** | CCNB1 | | | | | HOXB13 | | | CEACAM5 |
| **BAG1** | BAG1 | | | | | CALM2 | | | NDRG1 |
| **GRB7** | GRB7 | | | | | DHCR7 | | | SLCTA5 |
| **MMP11** | MMP11 | | | | | NEK2 | | | |
| **MYBL2** | MYBL2 | | | | | HBB | | | |
| **PGR** | PGR | | | | | PGR | | | |
| **ESR1** | ESR1 | | | | | ESM1 | | | |
| **HER2** | HER2 | | | | | HER2 | | | |
| **K67** | K67 | | | | | RACGAP1 | | | |
| **RPLPO** | RPLPO | | | | | IL6ST | | | |
| **TRPC** | TRPC | | | | | OA1 | | | |
| **SQUASK2** | SQUASK2 | | | | | MGP | | | |
| **ACTB** | ACTB | | | | | MGAM | | | |
| **CD68** | CD68 | | | | | MHC1 | | | |
| **GAPDH** | GAPDH | | | | | RAB5B | | | |
| **GSTM1** | GSTM1 | | | | | RAB5F | | | |
| **GUS** | GUS | | | | | RAB5G | | | |
| **STK15** | STK15 | | | | | RAB5J | | | |
| **CTSL2** | CTSL2 | | | | | RAB5L | | | |
| **CDCA1** | CDCA1 | | | | | RAB5M | | | |
| **CDH3** | CDH3 | | | | | RAB5P | | | |
| **EXO1** | EXO1 | | | | | RAB5Q | | | |
| **FGFR4** | FGFR4 | | | | | RAB5S | | | |
| **FOX5** | FOX5 | | | | | RAB5T | | | |
| **FOX01** | FOX01 | | | | | RAB5U | | | |
| **GPR160** | GPR160 | | | | | RAB5V | | | |
| **KIF1C** | KIF1C | | | | | RAB5W | | | |
| **KRT14** | KRT14 | | | | | RAB5X | | | |
| **KRT17** | KRT17 | | | | | RAB5Y | | | |
| **KRT5** | KRT5 | | | | | RAB5Z | | | |
| **MAPT** | MAPT | | | | | RAB6 | | | |
| **MIM2** | MIM2 | | | | | RAB6A | | | |
| **R6** | R6 | | | | | RAB6B | | | |
| **M6A** | M6A | | | | | RAB6C | | | |
| **MK67** | MK67 | | | | | RAB6D | | | |
| **MLP** | MLP | | | | | RAB6E | | | |
| **MYC** | MYC | | | | | RAB6F | | | |
| **NAT1** | NAT1 | | | | | RAB6G | | | |
| **UBE2T** | UBE2T | | | | | RAB6H | | | |
| **CENPF** | CENPF | | | | | RAB6I | | | |
| **CEP55** | CEP55 | | | | | RAB6J | | | |
| **CCNE1** | CCNE1 | | | | | RAB6K | | | |
| **ANLN** | ANLN | | | | | RAB6L | | | |
| **SFRP1** | SFRP1 | | | | | RAB6M | | | |
| **SLC39A8** | SLC39A8 | | | | | RAB6N | | | |
| **TMEM45B** | TMEM45B | | | | | RAB6O | | | |
| **TYMS** | TYMS | | | | | RAB6P | | | |
| **PHGDH** | PHGDH | | | | | RAB6Q | | | |
| **PTT1** | PTT1 | | | | | RAB6R | | | |
| **RRM2** | RRM2 | | | | | RAB6S | | | |
| **QSCML1** | QSCML1 | | | | | RAB6T | | | |
| **RAB8B** | RAB8B | | | | | RAB6U | | | |
| **RASSF7** | RASSF7 | | | | | RAB6V | | | |
| **RFL5** | RFL5 | | | | | RAB6W | | | |
| **RFC4** | RFC4 | | | | | RAB6X | | | |
| **RTN4RL1** | RTN4RL1 | | | | | RAB6Y | | | |
| **RUNDC1** | RUNDC1 | | | | | RAB6Z | | | |
| **M54AT** | M54AT | | | | | RAB7 | | | |
| **SERF1A** | SERF1A | | | | | RAB7A | | | |
| **SLC2A3** | SLC2A3 | | | | | RAB7B | | | |
| **TGFBI** | TGFBI | | | | | RAB7C | | | |
| **TSPYL5** | TSPYL5 | | | | | RAB7D | | | |
| **UCIL5** | UCIL5 | | | | | RAB7E | | | |
| **WISP1** | WISP1 | | | | | RAB7F | | | |
| **ZNF32** | ZNF32 | | | | | RAB7G | | | |
substrate requirement, surpasses enzymes’ thermal instability, and provides quick analysis.

In conclusion, by offering a quick, simple, and inexpensive diagnostic tool, especially in BC, the biosensor market is growing exponentially and is expected to surpass approximately US$40 billion by 2022 (Pfeifer, 2018). Despite all that, further research is needed to increase the detection sensitivity in almost all biosensors.

**ADVANCED BC DETECTION SYSTEMS**

**Multiple Gene Prognostic Assays**

In the era of big data, analyzing the large number of sequences (DNA, RNA, and protein array) from various studies can help devise a systemic strategy combating BC. Several genetic aberrations in women have a predisposition to BC. Incorporating genes that have been implicated in BC as a potential biomarker can provide an advantage in early BC detection and treatment (Walsh et al., 2011). With multigene signature analysis alongside other molecular tools, clinicians can now devise appropriate therapies and predict their outcome while minimizing detrimental effects. Currently, there are seven prognostic multigene signature analyzing tests for BC. However, not all are FDA approved. Some are recommended by agencies, such as the ASCO, American-National Comprehensive Cancer Network (NCCCN), and the European Society of Medical Oncology (ESMO) in their guidelines.

**Breast Cancer Index Test**

BCI test is a multigene assay developed by Biotheranostics Inc. It records: 1) a set of five proliferative gene expressions (BUB1B, CENPA, NEK2, RACGAPI1, and RRM2), termed as molecular grade index (MGI), and 2) a gene ratio of HOXB13: IL17BR (H: I), in predicting the BC outcome (Sgroi et al., 2013) (Table 1). The study compared BCI and IHC4 for their predictive ability in early and late recurrence in postmenopausal-ER+ patients with node-negative BC who participated in the clinical trial for arimidex, tamoxifen, alone or in combination (Sgroi et al., 2013). The linear BCI model showed significant prognostic value for risk of both early and late distant recurrence. Consistent results were reported in the Stockholm TAM cohort (Zhang et al., 2013), where BCI was able to identify two risk populations in both early and late distant recurrence and aiding in residual risk management after 5 years. In ASCO 2020 meeting, Biotheranostics’s Trans-aTTOM study delivered more evidence on BCI as a powerful prognostic tool informing the risk-benefit for extending adjuvant therapy (Bartlett et al., 2020). However, the BCI scores can only be used as an adjunct tool to the operating physician’s practice because it relies on the correlation with the patient's clinicopathological study. In conclusion, though its implications are worth considering in clinical research, it has still not been approved by the FDA.

**MammaPrint Test**

The MammaPrint test developed by Agendia is a genomic test used for early-stage BC diagnosis. NCCN, ESMO, and ASCO have recommended molecular signature analysis of 70 genes for primary BC prognosis (Cardoso et al., 2016) (Table 1). Its FDA’s approval as a prognostic test stratifies early-staged hormonal BC into low vs. high-risk for relapse (Van De Vijver et al., 2002). The ASCO guidelines of 2017 incorporate MammaPrint test scores to guide on therapy required for high-risk HR+/HER2- with node-negative breast carcinoma (Krop et al., 2017). The guidelines further state that “MammaPrint assay may assist in decisions on withholding the therapy in patients with one to three positive nodes and high clinical risk, provided that the patient should be informed that a benefit from chemotherapy cannot be excluded” (Krop et al., 2017). Extensive validation studies were performed before the MammaPrint tool became the standard of care. The Microarray In Node negative disease may Avoid Chemotherapy (MINDACT) study on 6,693 women with early-stage BC observed that the 70-genes analysis was able to detect even small aggressive tumors and was able to spare chemotherapy in patients with high clinical risk and low genomic risk of recurrence (ROR) (Cardoso et al., 2016). Therefore, the circumvention of chemotherapy in postmenopausal women with a low-risk of recurrence (as per the MammaPrint test) showcases its clinical utility as a prognostic genomic test (Cardoso et al., 2020). However, in TNBC and HER2+ BC, MammaPrint tests are not recommended until additional studies and results met the ASCO requirements.

**Mammostrat Test**

In contrast to multigene tests, Mammostrat is a five-protein based IHC assay (Table 1). It analyzes proteins (TP53, NDRG1, CEACAM5, HTP9C, and SLC7A5) that have been implicated in BC recurrence (Ring et al., 2006). The test score stratifies early-staged luminal BC with node-negative or positive carcinoma into low-risk to high-risk patients (Bartlett et al., 2010). Mammostrat test evaluates early-stage BC patients on tamoxifen therapy, analyzing and informing them of adjuvant therapy’s benefits. Like BCI, it is an adjuvant factor for BC evaluation. As per ASCO
guidelines, patients with HR⁺/HER2⁻ with node-negative or negative breast carcinoma are moderately not recommended for the Mammostrat test. But, for TNBC or HER2⁺ patients, the Mammostrat test is strictly not recommended.

**IHC4 Test**

IHC4 is a hormonal receptor protein-based assay focuses on four primary proteins, ER, PR, HER2, and Ki67 expressions, which were previously used as biomarkers to define surrogate molecular subtypes. Unlike BCI, IHC4 evaluates protein expressions, none of which is translated by BCI associated genes. As an independent tool, IHC4 combines the information from four biomarker proteins (Cuzick et al., 2011) to predict patients’ prognosis (Table 1). A modified version of IHC4 (mIHC4) was recently suggested for ER⁺/HER2⁻ metastatic BC patients (Jin et al., 2020), guiding on chemo or endocrine therapy. However, IHC4 is not recommended for TNBC and HER2 carcinoma (Harris et al., 2016), and the ASCO guidelines have not endorsed the use of IHC4 due to its unsatisfactory reproducibility (Cuzick et al., 2011).

**EndoPredict Test**

EP is a twelve multigene signature assay developed by Myriad Genetics (Table 1). It examines biopsied tumor tissue for eight cancer-related genes, three RNA-reference gene, and one DNA-reference gene (Filipits et al., 2011). The test score (EPclin Risk Score) that reflects tumor size and nodal status stratifies BC as low or high risk for distant metastasis (Filipits et al., 2012). In the GEICAM trial, EPclin Risk Score was used as an independent prognostic parameter for ER⁺/HER2⁻ BC with node-negative patients treated with chemotherapy followed by hormonal therapy (Martin et al., 2014). According to the ASCO guidelines, EPclin Risk Score may also be employed in the decision-making process as an adjuvant factor in ER⁺/PR⁺ HER2⁻ node-negative BC patients. However, for HER2⁺ and TNBC with node-positive breast carcinoma, ASCO doesn’t recommend EPclin Risk Score due to insufficient evidence for its usefulness (Harris et al., 2016).

**Prosigna/Prediction Analysis of Microarray50 Test**

Prosigna, formerly known as Prediction Analysis of Microarray50 (PAM50), is a RNA-based gene molecular signature assay developed by NanoString Technologies (Martin et al., 2014). This assay helps profile a patient’s tumor and understand its behavior. It includes analysis models to evaluates relapse/recurrence based on BC’s intrinsic hormonal subtyping, developed by Parker et al. (Parker et al., 2009). In Prosigna, the RNA extracted from the biopsied tumor sample is analyzed to provide information on the subtype involved and predict the tumor’s recurrence. The analysis is based on the Prediction Analysis of Microarray (PAM) signature assay (Martin et al., 2014) (Table 1), evaluating the activity of 58 genes by integrating NanoString’s nCounter technology to simplify the workflow without compromising its efficiency (Nielsen et al., 2014). The fluorescent probes used in nCounter technology bypasses mRNA amplification, thus saving time and material. The results are digitalized and later fed into an algorithm that translates tumor biology into actionable clinical results (Tibshirani et al., 2002). The algorithm includes hormonal expression and clinicopathological assessment of tumor based on its size and proliferative potential. The results scaled on 0–100, as the risk of relapse/recurrence (ROR) score, classifying node-negative cancers into low (0–40), intermediate (41–60), or high (61–100) risk, and node-positive cancers into low (0–40) or high (41–100) risk. According to the ASCO guidelines, a physician may use this signature assay alongside the clinicopathological parameters for high-risk HR⁺/HER2⁻ node-negative BC patients to select an adjuvant therapy (Harris et al., 2016). However, it doesn’t recommend using Prosigna score for the low-risk group, HER2⁺ and TNBC with node-positive breast carcinoma (Harris et al., 2016).

**Oncotype Dx Test**

Oncotype Dx is one of the most validated multigene signature assay, developed by Paik and colleagues (Paik et al., 2004) at Genomic Health, Inc. The ASCO guidelines incorporate it for the early-stage ER⁺/HER2⁻ node-negative BC patients with a high risk of recurrence Tian et al. (2008). It analyzes the RNA expression of 21 genes implicated in cancer proliferation and treatment response Tian et al. (2008) (Table 1). In conjunction with the patient’s age, the algorithm calculates a score between 0 and 100 as an Oncotype Dx Recurrence Score (RS), stratifying early-stage BC into a group of low, intermediate, and high risk of recurrence. In the low risk (RS < 18) group, chemotherapy benefits outweigh the risk of side effects, wherein high risk (RS > 31) group, chemotherapy benefits should surpass the rise of side effects. In this manner, the intermediate (RS 18-31) groups are the most volatile ones, with uncertainty whether chemotherapy outweighs the side effects or not. With recent technological advancement and research in GEP, an optimization was made in the RS cutoff (Sparano et al., 2015). In the Tailor-Dx phase-3 trial study, Sparano and colleagues confirmed its usefulness in guiding adjuvant systemic therapy (Sparano et al., 2015) in women older than 50 years. According to the authors, chemotherapy can be avoided in 1) women older than 50 years with RS 11-15, 2) women younger than 50-year-old with RS 11-16, and 3) women with RS 0-10. Chemotherapy followed by hormonal therapy were assigned for women with RS > 25. ASCO guidelines advise against the application of chemotherapy for the early-staged HR⁺/HER2⁻ node-negative BC patients with low risk of recurrence. The guidelines provide no direct assessment in intermediate RS patients; instead, they refer to TAILORx’s recommendation alongside traditional prognostic factors (Andre et al., 2019). The guidelines further indicate that the Oncotype Dx test should not be used in HER2⁺ and TNBC (Harris et al., 2016; Krop et al., 2017).

Most of the multigene assays have overlapping target genes in their analysis (Figure 5). Though multigene prognostics are an effective means of detection, different prognostics’ results tell a different tale. A comparative study on 1) MammaPrint and Oncotype Dx RS (Nunes et al., 2016; Tsai et al., 2018), 2) Oncotype Dx and Prosigna (Dowsett et al., 2013), 3)
TransATAC study on six different tests: EP, IHC4, Oncotype DX, BCI, Prosigina, and clinical treatment score (that evaluates nodal status, tumor size, grade, age, and endocrine treatment beyond 5 years) (Sestak et al., 2018), observed different prognostics information in their patients. A discordance in findings reflects the importance of integrating additional factors such as clinicopathological information with genomic imprint analysis (Kwa et al., 2017).

CONCLUSION AND FUTURE PERSPECTIVES

Despite large number of research articles published on BC diagnosis and treatment, research in its early detection still lags. Although several techniques have been developed in the last decade permitting detection and guidance on specific therapies, individual techniques’ pros and cons limit their utilization as a standalone tool. To plan a proper treatment, understanding the tumor’s molecular heterogeneity is crucial. An acute stratification is necessary as each group or sub-group exhibits individual prognosis and systemic therapy. Luminal A and B have an overlapping hormonal expression but have different prognosis and treatments. HER2+ BC exhibits a better prognosis and shows a promising outcome upon merging chemotherapy with anti-HER2 monoclonal antibodies and tyrosine kinase inhibitor-based therapies. TNBC remains a challenge to treat. Recent studies have suggested that analyzing BC molecular subtypes can give better information on recurrence and treatment response.

The traditional classifications that include IHC-hormone evaluations, GEP analysis, and examining pathological features have become clinically more affordable in routine processes. However, gene transcription does not necessarily correlate with protein expression. Numerous factors, such as mRNA transcription rate, protein stability, post-translational modifications, and random mutations, also affect protein biomarkers’ therapeutic potential. Several genetic mutations predispose BC in women. Therefore, for a complete understanding of pathological changes in BC, a high-throughput analysis of data extracted from several “omics” studies is needed to interpret biomarkers and pathways involved.

The pursuit of suitable BC biomarkers took us in the era of big data or the era of “BC-Omics.” Genomics, metabolomics, and proteomics with predictive and prognostic BC biomarkers have laid the foundation of various multigene assays for early detection and treatment strategy. Currently, there are seven prognostic signature tests available for BC, MammaPrint, Breast Cancer Index, IHC4, EndoPredict, Prosigina, Mammostrat, and Oncotype DX. Of the seven tests, Mammostrat and IHC4 are protein-based tests, while others are multi-gene-based screening. With multigene signature analysis alongside other molecular tools, clinicians can now select appropriate therapies and predict treatment duration more easily. A prognostic profile developed from multigene tests could better predict recurrence risk. Further, it could help avoid unnecessary treatments in low-risk patients so that they could resume their daily routines. As per ASCO guidelines, their use for screening BCs have not been approved. Clinical experts’ committees request more evidence to support multigene tests’ routine usage in HR+/HER2+ with node-positive BC in guiding adjuvant therapy. A comparative analysis of different multigene tests predicts distinct prognostics for the same patient, reflecting the importance of integrating clinicopathological information with genomic imprint analysis. Moreover, the cost of these tests is another obstacle for general use. Also, the expense of training the staff always remains an undervalued proposition that brings the challenge of maintaining the tests’ quality and reproducibility. Again, not all the tests are FDA approved. Additional clinical studies and results from large cohorts are needed to meet the ASCO requirements. There remains a gap between research findings and its clinical implementations. Several ongoing extensive cohort studies on BC, such as MINDACT, TAILORx, Trans-ATTOM, and many more, may provide positive impact on long-term patient outcome and guide the therapy.

Several clinical observations have found different treatment responses among diverse ethnic groups. In the era of personalized medicine, individualizing therapy is the next step in cancer treatment’s evolution. For a long time, human cell lines’ engraftment onto immunocompromized animals (Neve et al., 2006)—cell-derived xenografts (CDX)—have been used to understand BC genetics and its biological processes. With the advancement in understanding the importance of tumor microenvironment (Hanahan and Weinberg, 2011), the development of patient-derived xenografts (PDX) (Hoffman, 2015) circumvents the limitations with CDX. Unlike CDX, PDX models preserve the tumor’s heterogeneity, behavioral characteristics (metastasis), the microenvironment, and many other features. A unique advantage of PDX is its response to therapy (Tentler et al., 2012; Hidalgo et al., 2014). New models incorporate rare but aggressive BC (Wurth et al., 2015). Mimicking clinical trials of adjuvant therapy through experimental models such as PDX and syngeneic models will be significantly improved. Currently, these models of BC are amidst scientific debate in various immune-molecular societies (Varn et al., 2017) and are considered as mouse “avatars” for the patient (Holen et al., 2017). Besides, the immense amount of time and capital invested in such models’ development limits them to cohort-based preclinical studies. As such, a good in vivo model of BC is needed (Holen et al., 2017).

Furthermore, the discovery of the immune checkpoint proteins such as cytotoxic-T-lymphocyte-associated antigen-4 (CTLA-4) and Programmed Death-1 (PD-1) has led to a booming in immune-targeted therapies against tumors. Following targeted therapies’ strategy, oncolytic virus therapy (OVT) has shown potential in treating cancers, e.g., melanoma. Unlike gene therapy, where the virus is a carrier, OVT engineered the virus to target, infiltrate, multiply, and kill melanoma cells, leaving the normal cells unharmed. It includes four of the seven classes of viruses in the Baltimore classification system for BC treatment. Several scientific
studies have obtained encouraging results with OVT based immune-targeted therapy. Therefore, mono-therapeutic approaches are rarely the best treatment option for BC. Collaboration across disciplines appears more promising and gaining traction in personalized treatments. With increasing knowledge and the advancement in diagnostics and treatment strategies, BC will become better understood and more manageable.

AUTHOR CONTRIBUTIONS

MZ wrote the manuscript, SW and NA edited the manuscript.

REFERENCES

Alix-Panabères, C., and Pantel, K. (2014). Challenges in circulating tumour cell research. Nat. Rev. Cancer 14 (9), 623–631. doi:10.1038/nrc3820
Alzurg, E., Almalkari, A., Aldin, B., Hamoud, M., and Othman, S. (2016). New system for early breast cancer detection by Electrical impedance spectroscopy. Recent Adv. Environ. Sci. Biomed. 4, 142–150.
Amioka, A., Masumoto, N., Gouda, N., Kajitani, K., Shigematsu, H., Emi, A., et al. (2016). Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy. Ipmn. J. Clin. Oncol. 46 (4), 303–309. doi:10.1093/ijco/iyv215
Anbar, M. (1998). Clinical thermal imaging today. IEEE Eng. Med. Biol. Mag. 17 (4), 25–33. doi:10.1109/51.687960
Andre, F., Ismaila, N., Henry, N. L., Somer Arkan, E., Saber, R., Karimi, Z., and Shamsipur, M. (2015). A novel antibody-Arizzti, P., Fang, L., Park, I., Yin, Y., Solomon, E., Ouchi, T., et al. (2000). Tumor suppressor p53 is required to modulate BRCA1 expression. Mol. Cell Biol. 20 (20), 7450–7459. doi:10.1128/mcb.20.7450-7459.2000
Arkan, E., Saber, R., Karimi, Z., and Shamsipour, M. (2015). A novel antibody-antigen based impedimetric immunosensor for low level detection of HER2 in serum samples of breast cancer patients via modification of a gold nanoparticles decorated multiwall carbon nanotube-ionic liquid electrode. Anal. Chim. Acta 874, 66–74. doi:10.1016/j.aca.2015.03.022
Arteaga, C. L., Sławkowski, M. X., Osborne, C. K., Perez, E. A., Pugliasi, F., and Gianni, L. (2012). Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 9 (1), 16–32. doi:10.1038/nrclinonc.2011.177
Arya, S. K., Wang, K. Y., Wong, C. C., and Rahman, A. R. (2013). Anti-EpCAM decorating multiwall carbon nanotube-ionic liquid electrode. Frontiers in Pharmacology | www.frontiersin.org February 2021 | Volume 11 | Article 632079
Bacelli, I., Schneeweiss, A., Riethdorf, S., Stenzinger, A., Schillert, A., Vogel, V., et al. (2013). Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31 (6), 539–544. doi:10.1038/nbt.2576
Barazi, H., and Gundurau, M. (2019). Mammography BI RADS grading. StatPearls. Treasure Island, FL: StatPearls Publishing.
Bardou, V. J., Arpino, G., Elledge, R. M., Osborne, C. K., and Clark, G. M. (2003). Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21 (10), 1973–1979. doi:10.1200/JCO.2003.09.099
FUNDING

This publication was made possible by the Arkansas INBRE program, supported by a grant from the National Institute of General Medical Sciences, (NIGMS), P20 GM103429 from the National Institutes of Health.

ACKNOWLEDGMENTS

The authors would like to thank Mr. Lauv Patel of University of Arkansas at Little Rock for his help during editing the manuscript.

Barlett, J., Sgroi, D. C., Treuner, K., Zhang, Y., Piper, T., Salunga, R. C., et al. (2020). HER2 status and prediction of extended endocrine benefit with breast cancer index (BCI) in HR+ patients in the adjuvant tamoxifen: to offer more?(ttTom) trial. J. Clin. Oncol. 38 (15_suppl), 522. doi:10.1200/JCO.2020.38.15_suppl.522
Bartlett, J. M., Thomas, J., Ross, D. T., Seitz, R. S., Ring, B. Z., Beck, R. A., et al. (2010). Mammocrin as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res. 12 (4), R47. doi:10.1186/bcr2604
Begam, N., Jamil, K., and Raju, S. G. (2017). Promoter hypermethylation of the MCRNA gene as a novel biomarker for breast cancer. Asian Pac. J. Cancer Prev. APJC 18 (11), 3003. doi:10.22034/aijpcp.2017.18.11.3003
Behling, K. C., Tang, A., Freydin, B., Chervoneva, I., Kadakia, S., Schwartz, G. F., et al. (2011). Increased SIAH expression predicts ductal carcinoma in situ (DCIS) progression to invasive carcinoma. Breast Cancer Res. Treat. 129 (3), 717–724. doi:10.1007/s10549-012-1548-8
Benvidi, A., Dehghani Firouzabadi, A., Dehghani Tezerjani, M., Moshtaghian S., M., Mazloum-Ardakani, M., and Ansarin, A. (2015). A highly sensitive and selective electrochemical DNA biosensor to diagnose breast cancer. J. Electroanalytical Chem. 750, 57–64. doi:10.1016/j.jelechem.2015.05.002
Bertwistle, D., Swift, S., Marston, N. J., Jackson, L. E., Crossland, S., Crompton, M. R., et al. (1997). Nuclear location and cell cycle regulation of the BRCA2 protein. Cancer Res. 57 (24), 5485–5488.
Blanco-Prieto, S., Barcia-Castro, L., Plas de la Cadena, M., Rodriguez-Berrocal, F. J., Vázquez-Iglesias, L., Botana-Rial, M. L., et al. (2017). Relevance of matrix metalloproteinases in non-small cell lung cancer diagnosis. BMC cancer 17 (1), 823. doi:10.1186/s12885-017-3842-2
Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jr, Jacobs, S. A., et al. (2017). Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46–USOR 07132, and NSABP B-49 (NRG oncology). J. Clin. Oncol. 35 (23), 2647. doi:10.1200/JCO.2016.71.4147
Borichker, K., Islam, M. N., Gopalan, V., Lam, A. K., Nguyen, N. T., and Shiddiky, M. J. A. (2017). Quantum dot-based sensitive detection of disease specific exosome in serum. Analyst 142 (12), 2211–2219. doi:10.1039/c7an00672a
Bourdje, J. C., Khoury, M. P., Driot, A., Baker, L., Fernandez, K., Aoubala, M., et al. (2015). p53 breast cancer patients expressing p53ly have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Res. 13 (1), R7. doi:10.1186/s13058-015-02811
Boyd, N. F., Guo, H., Martin, J. L., Sun, L., Stone, J., Fishell, E., et al. (2007). Mammographic density and the risk and detection of breast cancer. N. Engl. J. Med. 356 (3), 227–236. doi:10.1056/NEJMoa062790
Brekelmans, C., Seynave, C., Menke-Pluymers, M., Brüggeworth, H., Tilanus-Linthorst, M., Bartels, C., et al. (2006). Survival and prognostic factors in BRCA1-associated breast cancer. Ann. Oncol. 17 (3), 391–400. doi:10.1093/annonc/mdz095
Brekelmans, C., Tilanus-Linthorst, M., Seynave, C., vd Ouweland, A., Menke-Pluymers, M. B., Bartels, C. C., et al. (2007). Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur. J. Cancer 43 (5), 867–876. doi:10.1016/j.ejca.2006.12.009
Brem, R. F., Tabár, L., Duffy, S. W., Incardi, M. F., Guingrich, J. A., Hashimoto, B. E., et al. (2015). Assessing improvement in detection of breast cancer with three-dimensional automated breast US in women with dense breast tissue: the Somolnsight Study. Radiology 274 (3), 663–673. doi:10.1148/radiol.14132832
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänécke, F., et al. (2001). Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB1- and/or ErbB2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J. Clin. Oncol. 19 (18), 3808–3816. doi:10.1200/JCO.2001.19.18.3808

Ellis, M. J., Tao, Y., Young, O., White, S., Proia, A. D., Murray, J., et al. (2006). Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J. Clin. Oncol. 24 (19), 3019–3025. doi:10.1200/JCO.2005.04.3034

Evans, D., Howell, A., Ward, D., Laloo, F., Jones, J., and Eccles, D. (2011). Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J. Med. Genet. 48 (8), 520–522. doi:10.1136/jmedgenet-2011-100006

Felix, R. T., Veiga, M. G., Carelli Filho, I., Souto, R. P. D., Fernandes, C. E., and Oliveira, E. (2018). Association between matrix metalloproteinase 9 polymorphism and breast cancer risk. Rev. Bras Ginecol Obstet. 40 (10), 620–624. doi:10.15955/s0038-1673x366

Feng, L., Chen, Y., Ren, J., and Qu, X. (2011). A graphene functionalized electrochemical aptasensor for selective label-free detection of cancer cells. Biomaterials 32 (11), 2930–2937. doi:10.1016/j.biomaterials.2011.01.002

Filipits, M., Rudas, M., Jakész, R., Dusbky, P., Pitákl, F., Singer, C. F., et al. (2011). A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Am. J. Cancer Res. 17 (8), 6012–6020. doi:10.1186/1758-083X-11-0926

Filipits, M., Dusbky, P. C., Rudas, M., Brase, J. C., Kronenwett, R., Weber, K. E., et al. (2012). Impact of the EndoPredict-clin score on risk stratification in ER-positive, HER2-negative breast cancer after considering clinical guidelines, Am. Soc. Clin. Oncol. 30 (15), 542. doi:10.1200/JCO.2012.30.15_suppl.542

Foulkes, W. D., Stefansson, I. M., Chappuis, P. O., Bégin, L. R., Gof

Hubbard, R. A., Kerlikowske, K., Flowers, C. I., Yankaskas, B. C., Zhu, W., and Hub, R., Wen, W., Wang, Q., Xiong, H., Zhang, X., Gu, H., et al. (2014). Novel electrochemical aptamer biosensor based on an enzyme-gold nanoparticle dual label for the ultrasensitive detection of epithelial tumour marker MUC1. Biosens. Bioelectron. 35, 384–389. doi:10.1016/j.bios.2013.10.015

Holen, I., Speirs, V., Morrissey, B., and Blyth, K. (2017). In vivo models in breast cancer research: progress, challenges and future directions. Dis. Model Mech. 10 (4), 359–371. doi:10.1242/dmm.028274

Hoon Tan, P., Ellis, I., Allison, K., Brogi, E., Fox, S. B., Lakhani, S., et al. (2020). The 2019 WHO classification of tumours of the breast. Histopathology 77 (2), 181–185. doi:10.1111/his.14091

Hu, R., Lu, W., Qiu, X., Zhang, H., Zhang, X., Gu, H., et al. (2014). Novel electrochemical aptamer biosensor based on an enzyme-gold nanoparticle dual label for the ultrasensitive detection of epithelial tumour marker MUC1. Biosens. Bioelectron. 35, 384–389. doi:10.1016/j.bios.2013.10.015

Hubbard, R. A., Kerlikowske, K., Flowers, C. I., Yankaskas, B. C., Zhu, W., and Miglioretti, D. L. (2011). Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann. Intern. Med. 155 (8), 481–492. doi:10.17372348-0003-4189-1558-8-20111080-00004

Hwang, L. A., Pang, B. H., Liew, O. W., Iqbal, J., Koh, X. H., Koh, X. Y., et al. (2018). Monoclonal antibodies against specific p53 hotspot mutants as potential tools for precision medicine. Cell Rep. 22 (1), 299–312. doi:10.1016/j.celrep.2017.11.112

Jin, L., Chen, K., Tan, C., Li, J., Luo, J., Yang, Y., et al. (2020). Prognostic value of modified IHC4 score in patients with estrogen receptor–positive metastatic breast cancer. Oncologist 25 (8), e1170–e1180. doi:10.1634/theoncologist.2019-1006

Jossinet, J. (1996). Variability of impedance in normal and pathological breast tissue. Med. Biol. Eng. Comput. 34 (5), 346–350. doi:10.1016/0025-7567(96)00002-3

Karami, F., and Mehdipour, P. (2013). A comprehensive focus on global spectrum of breast cancer. Acta Radiol. 55 (10), 1174–1179. doi:10.1177/0284185113514051

Karanenas, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144 (5), 646–674. doi:10.1016/j.cell.2011.02.013

Kari, F., and Mehdipour, P. (2013). A comprehensive focus on global spectrum of breast cancer. Acta Radiol. 55 (10), 1174–1179. doi:10.1177/0284185113514051

Kim, B. K., Lee, J. W., Park, P. J., Shin, Y. S., Lee, W. Y., Lee, K. A., et al. (2009). The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res. 11 (2), R22. doi:10.1186/bcr2247
Yousef, E. M., Tahir, M. R., St-Pierre, Y., and Gaboury, L. A. (2014). MMP-9 expression varies according to molecular subtypes of breast cancer. *BMC cancer* 14 (1), 609–612. doi:10.1186/1471-2407-14-609

Zhang, H. Y., Liang, F., Jia, Z. L., Song, S. T., and Jiang, Z. F. (2013). Mutation, methylation and expression in breast cancer patients. *Oncol. Lett.* 6 (1), 161–168. doi:10.3892/ol.2013.1331

Zhang, J., Wu, D. Z., Cai, S. X., Chen, M., Xia, Y. K., Wu, F., et al. (2016). An immobilization-free electrochemical impedance biosensor based on duplex-specific nuclease assisted target recycling for amplified detection of microRNA. *Biosens. Bioelectron.* 75, 452–457. doi:10.1016/j.bios.2015.09.006

Zhang, L., Ralghway, L. D., Wetzel, M. D., Ngo, J., Yin, W., Kumar, D., et al. (2013). The identification and characterization of breast cancer CTCs competent for brain metastasis. *Sci. Transl. Med.* 5 (180), 180ra48. doi:10.1126/scitranslmed.3005109

Zhang, L., Xiao, H., Karlan, S., Zhou, H., Gross, J., Elashoff, D., et al. (2010). Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. *PloS one* 5 (12), e15573. doi:10.1371/journal.pone.0015573

Zhao, J., Wu, J., Cai, H., Wang, D., Yu, L., and Zhang, W.-H. (2016). E3 Ubiquitin ligase Siah-1 is down-regulated and fails to target natural HBx truncates for degradation in hepatocellular carcinoma. *J. Cancer* 7 (4), 418. doi:10.1158/1078-0432.CCR-13-0804

Zhou, J., Liu, T., and Wang, W. (2018). Prognostic significance of matrix metalloproteinase 9 expression in osteosarcoma: a meta-analysis of 16 studies. *Medicine* 97 (44), e13051. doi:10.1097/md.0000000000013051

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2021 Zubair, Wang and Ali. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**
GLOSSARY

AB, ABUS Automated breast ultrasonography;
AI Aromatase inhibitor
APCs Antigen-presenting cells
AR Androgen receptor
ASCO American Society of Clinical Oncology
AT, ATM Ataxia Telangiectasia, Ataxia Telangiectasia mutation
BC Breast cancer(s)
BI-RADS Breast imaging reporting and data system
BL Basal-like
BLIA Basal-like-immune-activated
BLIS Basal-like-immune-suppressive
BRCA1/2 Breast cancer genes-1/-2
BRE Biochemical recognition element
CA Cancer antigen
cDNA Complementary DNA
CDX Cell-derived Xenografts
CES-MRI Chemical exchange saturation transfer MRI
CEUS Contrast-enhanced ultrasonography
CTCs Circulating tumor cells
CTLA-4 Cytotoxic-T-lymphocyte-associated antigen
DBT Digital breast tomosynthesis
DCE-MRI Dynamic contrast-enhanced MRI
DCIS Ductal carcinoma in situ
DIET Digital image-based elasto-tomography
DITI Digital infrared thermal imaging
EIS Electrical impedance scanning/spectroscopy
ELISA Enzyme-linked immunosorbent assay
EMT Epithelial-mesenchymal transition
EP EndoPredict
ER Estrogen receptors
ERα/PR Estrogen and Progesterone receptor
ER+, ER− ER-positive, ER-negative
ESMO European society of medical oncology
GD-DTPA Gadolinium diethylenetriamine pentaacetic acid
GEP Gene expression profiling
HELU Hyperplastic enlarged lobular unit
HER2 Human epidermal growth factor receptor 2
HER2-ECD Extracellular domain of HER2
IARC International Agency for Research on Cancer
IBC Invasive breast carcinoma
IBC-NE Invasive breast carcinoma with neuroendocrine differentiation
IDC Invasive ductal carcinoma
IGF Insulin-like growth factor
IHC Immune histochermo/compatibility
ILC Invasive lobular carcinoma
IM Immunomodulatory
INSM1 Insulinoma-associated protein 1
LAR Luminal androgen receptor
LncRNA Long non-coding RNAs
LCIS Lobular carcinoma in situ
M Mitotic rate
MAPP Multiple affinity protein profile
MGI Molecular grade index
MES Mesenchymal-like triple-negative breast cancer subtype
MMP Matrix metalloproteinase
MMP-9 Matrix metalloproteinase-9
MRI Magnetic resonance imaging
MSC Mammary stem cell
MUC1 Mucin-1
N Degree of nuclear polymorphism (Nodes)
NAAs Nucleic acid aptamers
NCCN American-national comprehensive cancer network
NE Neuroendocrine
NET Neuroendocrine tumor
NGS Next-gene sequencing
NOS Not otherwise specified
NPI Nottingham prognosis Index
NSE Neuron-specific enolase
NST No special type
OVT Oncolytic virus therapy
PD-1 Programmed death-1
PDX Patient-derived xenografts
PR Progesterone receptors
PTEN Phosphatase and tensin homolog
PTM Post-translational modification
QDs Quantum dots
SEREX Serological analysis of tumor antigens by recombinant cDNA expression cloning
SERM Selective estrogen receptor modulators
| Acronym | Description |
|---------|-------------|
| SERPA   | Serological proteome assay |
| SIAH    | Seven in absentia homolog |
| SPR     | Surface plasmon resonance |
| T       | Tubular structures |
| TAABs   | Tumor-associated autoantibodies |
| TAAbs   | Tumor-associated antigens |
| TCCRP   | Tall cell carcinoma with reverse polarity |
| TILs    | Tumor-infiltrating lymphocytes |
| TNBC    | Triple-negative breast cancer |
| WT      | Wild type |